Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Up 18.1% in July

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) was the recipient of a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 4,240,000 shares, a growth of 18.1% from the June 30th total of 3,590,000 shares. Approximately 11.7% of the company’s shares are sold short. Based on an average daily volume of 338,400 shares, the days-to-cover ratio is currently 12.5 days.

Wall Street Analyst Weigh In

YMAB has been the topic of several recent research reports. Truist Financial assumed coverage on Y-mAbs Therapeutics in a report on Friday, June 28th. They set a “buy” rating and a $21.00 price target on the stock. HC Wainwright raised their target price on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Monday, May 13th. Two analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $17.86.

Insider Buying and Selling

In other news, insider Thomas Gad sold 7,351 shares of the company’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $13.00, for a total value of $95,563.00. Following the transaction, the insider now directly owns 232,681 shares in the company, valued at approximately $3,024,853. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Thomas Gad sold 7,351 shares of the firm’s stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total transaction of $95,563.00. Following the completion of the transaction, the insider now directly owns 232,681 shares in the company, valued at approximately $3,024,853. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Bo Kruse sold 31,371 shares of the business’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $12.07, for a total transaction of $378,647.97. Following the sale, the chief financial officer now owns 210,877 shares in the company, valued at $2,545,285.39. The disclosure for this sale can be found here. In the last ninety days, insiders sold 99,444 shares of company stock valued at $1,203,925. 21.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Campbell & CO Investment Adviser LLC acquired a new position in shares of Y-mAbs Therapeutics during the 4th quarter valued at about $562,000. Los Angeles Capital Management LLC boosted its stake in Y-mAbs Therapeutics by 17.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 356,530 shares of the company’s stock valued at $2,432,000 after acquiring an additional 52,610 shares during the last quarter. Sapient Capital LLC bought a new stake in shares of Y-mAbs Therapeutics in the 4th quarter valued at approximately $298,000. Federated Hermes Inc. raised its holdings in shares of Y-mAbs Therapeutics by 4,708.0% during the fourth quarter. Federated Hermes Inc. now owns 44,474 shares of the company’s stock worth $303,000 after purchasing an additional 43,549 shares during the period. Finally, Boston Partners bought a new position in Y-mAbs Therapeutics in the first quarter worth about $556,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Price Performance

Shares of NASDAQ:YMAB opened at $12.15 on Tuesday. Y-mAbs Therapeutics has a 1-year low of $4.60 and a 1-year high of $20.90. The firm has a fifty day moving average price of $12.09 and a 200 day moving average price of $13.62. The stock has a market cap of $533.18 million, a P/E ratio of -24.80 and a beta of 0.66.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). The company had revenue of $19.93 million for the quarter, compared to analyst estimates of $22.06 million. Y-mAbs Therapeutics had a negative return on equity of 21.40% and a negative net margin of 25.64%. Sell-side analysts expect that Y-mAbs Therapeutics will post -0.52 EPS for the current fiscal year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.